Press Releases

ERP Article: Actualising the Power of Antibody-Drug Conjugates as Cancer Therapeutics

In the latest issue of European Pharmaceutical Review, our CEO,  Dominik Schumacher, and our CSO, Jonas Helma-Smets, discuss the advancements in the field since the approval of the first ADC generation and explain how Tubulis’ innovative conjugation platforms enable the creation of uniquely matched ADCs to address current shortcomings like narrow therapeutic windows, off-target toxicities and limitations for certain indications.

Read the full article here.


For Tubulis
Dominik Schumacher,
CEO & Co-Founder
Phone: +49 175 800 5594

Media Requests for Tubulis
Trophic Communications
Stephanie May or Marie Weickert
Phone: + 49 171 185 5682

Share Article

More Press Releases

Tubulis Presents Preclinical Data for Solid Tumor Targeting ADC Candidates TUB-030 and TUB-040 Demonstrating Superior Efficacy Profile and a Wide Therapeutic Window at the AACR Annual Meeting 2024

Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline

Tubulis to Present Preclinical Proof-of-Concept Data for Two Lead ADC Candidates Targeting Solid Tumors at the AACR Annual Meeting 2024